Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
On November 15, 2017, Xenetic Biosciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals and corresponding votes.
| 1. | The Company’s stockholders approved the election of the following seven nominees with each director receiving votes as follows: |
| Name | For | Withheld | BrokerNon-Votes |
| Jeffrey Eisenberg | 6,019,463 | 3,347 | – |
| Dr. James E. Callaway | 6,019,463 | 3,347 | – |
| Firdaus Jal Dastoor, FCS | 6,016,041 | 6,769 | – |
| Dr. Dmitry Genkin | 6,019,463 | 3,347 | – |
| Roman Knyazev | 6,019,363 | 3,447 | – |
| Dr. Roger Kornberg | 6,019,469 | 3,341 | – |
| Mr. Adam Logal | 6,019,469 | 3,341 | – |
| 2. | The Company’s stockholders voted upon and approved and adopted the Company’s Amended and Restated 2014 Equity Incentive Plan. The votes on the proposal were as follows: |
| For | Against | Abstained | BrokerNon-Votes |
| 649,506 | 10,132 | 5,363,172 | – |
| 3. | The Company’s stockholders voted upon the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017. The votes on this proposal were as follows: |
| For | Against | Abstained |
| 6,022,662 | – |
No other matters were considered or voted upon at the Annual Meeting.
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
